Evaluating patency rates of an ultralow-porosity expanded polytetrafluoroethylene covered stent in the treatment of venous stenosis in arteriovenous dialysis circuits
| Autor: | Karim Valji, Franklin J. Miller, Anshuman Bansal, Michael D. Kuo, Michael G. Chan |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors medicine.medical_treatment Vascular access Arteriovenous fistula Expanded polytetrafluoroethylene Kaplan-Meier Estimate Prosthesis Design Venous stenosis Blood Vessel Prosthesis Implantation Arteriovenous Shunt Surgical Recurrence Renal Dialysis medicine Clinical endpoint Humans Radiology Nuclear Medicine and imaging Polytetrafluoroethylene Dialysis Covered stent Vascular Patency Aged business.industry Graft Occlusion Vascular Thrombosis Middle Aged medicine.disease Surgery Blood Vessel Prosthesis Treatment Outcome Female Stents Radiology Cardiology and Cardiovascular Medicine business Porosity Angioplasty Balloon |
| Zdroj: | Journal of vascular and interventional radiology : JVIR. 25(2) |
| ISSN: | 1535-7732 |
| Popis: | Purpose To evaluate the efficacy of an ultralow-porosity expanded polytetrafluoroethylene (ePTFE) covered stent in the treatment of autogenous arteriovenous fistula (AVF) and prosthetic arteriovenous graft (AVG) venous outflow stenoses. Materials and Methods Clinical and angiographic outcomes of 20 consecutive patients with arteriovenous dialysis circuits treated with the endoprosthesis were reviewed following institutional review board approval. Patients were followed routinely at 2 months and 6 months after stent placement, or earlier if clinically warranted. The primary endpoint was 2- and 6-month primary treatment area patency. Secondary endpoints included primary circuit patency, primary assisted patency, and secondary patency. Results Eleven patients with AVFs and nine patients with AVGs were treated successfully with the covered stent. Primary treatment area patency rates were 85% ± 16 at both 2 months and 6 months. Primary circuit patency rates were was 65% ± 21 and 45% ± 22, respectively; primary assisted patency rates were 90% ± 13 and 85% ± 16, respectively; and secondary patency rates were 100% and 90% ± 13, respectively. Of the three cases of lost primary treatment area patency, two developed thrombosis and one developed recurrent stenosis. No significant differences were found between patients with AVFs and AVGs. Conclusions Data from this preliminary study suggests that the ultralow-porosity ePTFE covered stent may be a clinically viable option for treatment of venous outflow stenoses in arteriovenous vascular access circuits. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|